tavlesse
instituto grifols s.a. - Динатриевая fostamatinib - trombocitopenija - druge sistemske кровоостанавливающие - tavlesse je indiciran za liječenje kronične imunološki тромбоцитопении (ihs) u odraslih bolesnika, vatrostalne standardnim tretmanima na druge metode liječenja.
nplate
amgen europe b.v. - romiplostim - purpura, trombocitopenična, idiopatska - antihemorrhagics - adults:nplate is indicated for the treatment of primary immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroidi, imunoglobulini). paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e. kortikosteroidi, imunoglobulini).
revolade
novartis europharm limited - eltrombopag - purpura, trombocitopenična, idiopatska - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 i 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 i 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.
hemlibra
roche registration limited - emicizumab - hemofilija a - antihemorrhagics - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra mogu se koristiti u svim dobnim skupinama.
dicynone 250 mg/2 ml otopina za injekciju
novartis ba d.o.o. - этамзелат-Ферейн - otopina za injekciju - 250 mg/2 ml - 2 ml otopine za injekciju sadrži: 250 mg etamsilat
revolade 25 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - eltrombopag - filmom obložena tableta - 25 mg/1 tableta - 1 filmom obložena tableta sadrži: 25 mg eltrombopag (u obliku eltrombopag olamina)
revolade 50 mg/1 tableta filmom obložena tableta
novartis ba d.o.o. - eltrombopag - filmom obložena tableta - 50 mg/1 tableta - 1 filmom obložena tableta sadrži: 50 mg eltrombopag (u obliku eltrombopag olamina)
dicynone 250 mg/2 ml otopina za injekciju
sandoz d.o.o. - этамзелат-Ферейн - otopina za injekciju - 250 mg/2 ml - 2 ml otopine za injekciju sadrži: 250 mg etamsilat
eltrombopag alpha-medical 25 mg filmom obložene tablete
alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - eltrombopagolamin - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 25 mg eltrombopaga u obliku eltrombopagolamina
eltrombopag alpha-medical 50 mg filmom obložene tablete
alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - eltrombopagolamin - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 50 mg eltrombopaga u obliku eltrombopagolamina